Boundless Bio's reverse merger; CARsgen wins first solid tumor approval for CAR-T

Boundless Bio hands Nasdaq listing to Serapha Bio in reverse merger with $230M in financing; CARsgen wins world's first CAR-T approval for solid tumors; plus uniQure, MoonLake, Definium, Versant, Corxel and US WorldMeds.

Raccontata daendpoints.news